A Cost-Effectiveness Analysis of EGFR-TK Mutation Status-Guided 1st- And 2nd-Line Treatment of Stage III/IV Non-Small Cell Lung Cancer in the UK

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.2281
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2018English

Egfr Test-Guided Erlotinib Versus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Budget Impact Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

EGFR Mutation Status in Tunisian Non-Small-Cell Lung Cancer Patients Evaluated by Mutation-Specific Immunohistochemistry

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2018English

Pcn134 - Use of Liquid Biopsy in Metastatic Non-Small Cell Lung Cancer With Egfr Mutation: A Cost Consequence Analysis.

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Applicability of a Prognostic CT-based Radiomic Signature Model Trained on Stage I-Iii Non-Small Cell Lung Cancer in Stage IV Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

Pcn44 - First-Line Treatment Efficacy in Egfr-Positive Non-Small Cell Lung Cancer: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2012English

P043 Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy